Influence of genetic variants in TPMT and COMT associated with cisplatin induced hearing loss in patients with cancer: two new cohorts and a meta-analysis reveal significant heterogeneity between cohorts.

Influence of genetic variants in TPMT and COMT associated with cisplatin induced hearing loss in patients with cancer: two new cohorts and a meta-analysis reveal significant heterogeneity between cohorts.

Treatment with cisplatin-containing chemotherapy regimens causes hearing loss in 40-60% of cancer patients. It has been suggested that genetic variants in the genes encoding thiopurine S-methyltransferase (TPMT) and catechol O-methyltransferase (COMT) can predict the development of cisplatin-induced...

Full description

Bibliographic Details
Main Authors: Melanie M Hagleitner, Marieke J H Coenen, Ana Patino-Garcia, Eveline S J M de Bont, Anna Gonzalez-Neira, Hanneke I Vos, Frank N van Leeuwen, Hans Gelderblom, Peter M Hoogerbrugge, Henk-Jan Guchelaar, Maroeska W M Te Loo
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4281251?pdf=render

Internet

http://europepmc.org/articles/PMC4281251?pdf=render

Similar Items